Introduction
============

The burden of type 2 diabetes mellitus among American Indians is disproportionately high with an estimated prevalence ranging between 34 and 68% compared to 9.3% in the general U.S. population ([@B1]; [@B21]). In addition to high prevalence, incidence is twice as high among American Indians compared to the U.S. general population ([@B43]; [@B28]). While largely attributed to the obesity epidemic, other risk factors especially among American Indians are not well understood, particularly genetic susceptibility ([@B31]; [@B11]; [@B13]; [@B47]).

Pathogenesis is increasingly being attributed to B cell dysfunction compared to insulin resistance in peripheral tissues ([@B32]). Heritability for HOMA-beta cell function (HOMA-B), HOMA-IR, type 2 diabetes mellitus are 0.28--0.78, 0.08--0.75, and 0.26--0.70, respectively ([@B18]; [@B27]; [@B34]; [@B2]). Several of the diabetes-associated genes, including *PPARG* and *SLC30A8*, initially identified in individuals of European ancestry, have also been replicated in other populations ([@B23]; [@B7]; [@B48]). Generalization to other ethnic groups has been limited, especially among American Indians ([@B11]; [@B10]; [@B15]). Genome-wide linkage analysis in Strong Heart Family Study (SHFS) has demonstrated segregation of diabetes and metabolic trait related variants among American Indian families ([@B31]; [@B11]). Yet, most genetic loci identified in other ancestries have not replicated in American Indians ([@B20]; [@B37]; [@B13]; [@B10]). The main goal of this study was to assess the associations between genetic variants previously associated with cardiometabolic traits and dysglycemia traits of HOMA-B, HOMA-IR, and incident diabetes in American Indians among SHFS participants who were free of diabetes at baseline and replicated significant associations in an independent sample from Southwestern Arizona.

Materials and Methods {#s1}
=====================

Study Population
----------------

The SHFS is an extension of a large, population-based cohort of American Indians in the Strong Heart Study (SHS), recruited from thirteen tribes from three centers: Arizona, Oklahoma and North and South Dakota. Details on participant recruitment and information obtained in clinical visits have been published ([@B22]; [@B30]). Briefly, the SHFS included family members with a core sibship including at least 5 living members of whom at least 3 had to be original SHS participants. Recruitment of the SHFS participants was conducted in two phases; 533 participants attended the baseline visit in 1998--99 and 1,941 participants attended the baseline visit in 2001--03. Follow-up examinations were performed in 2001--03, 2005--06, and 2014--15. Demographic and clinical characteristics were collected at baseline and follow-up visits, including fasting plasma glucose (FPG) and HbA1c. For this study, we included participants without diabetes at baseline since our primary outcome was HOMA-B. We further excluded individuals without measured phenotypic and genotypic data (*n* = 1,923). During follow-up, 256 participants developed diabetes. The replication sample included 3,244 participants from a community in Southwestern Arizona. Detailed information on participant recruitment and data have been described elsewhere ([@B19]; [@B14]).

All participants in this study provided written informed consent and tribal consent. The study protocols were approved by the Indian Health Service Institutional Review Board, by the Institutional Review Boards of the participating Institutions, and by the participating American Indian tribes.

Outcome Definition
------------------

HOMA-IR (mmol/L) was calculated by fasting insulin in mU/L ^∗^ fasting glucose in mmol/L)/22.5 ([@B24]). HOMA-B was calculated using baseline data of participants without diabetes, and the equation described by [@B24] (20 ^∗^ fasting insulin in mU/L)/(fasting glucose in mmol/L - 3.5). To incorporate the influence of insulin resistance, corrected HOMA-B (cHOMA-B) was created as the residuals when HOMA-B was regressed on HOMA-IR (HOMA-B = mean HOMA-B + beta coefficient ^∗^ HOMA-IR). Diabetes was defined as a fasting plasma glucose ≥ 6.99 mmol/L or use of insulin or oral hypoglycemic medications. Incident diabetes was defined as new cases during subsequent follow-up visits (mean follow-up 6.6 years, range 3.0--12.3 years).

Genotyping
----------

Blood DNA from baseline was genotyped using the Illumina Cardio-Metabo DNA Analysis BeadChip (MetaboChip) ([@B41]). MetaboChip included 196,725 single nucleotide polymorphisms (SNPs) selected based on meta-analysis of cardiometabolic traits and includes replication targets and fine-mapping regions. Samples were excluded when sample call rate \< 95%, mismatch between genotyped and reported gender, outlier in identity by descent (IBD) clustering, or outlier in principal components analysis (PCA). SNPs were excluded if: call rate \< 98% or no data (*n* = 33,604); not autosomal (*n* = 250); monomorphic (*n* = 158); or violated Hardy-Weinberg equilibrium (HWE) *P* \< 1 × 10^−5^ (*n* = 1,519). PCA was performed on a matrix of doses of copies of minor allele for SNPs selected among genotyped founders or unrelated individuals based on minimum spacing of 1 kb, minor allele frequency (MAF) ≥ 0.05, pairwise correlation of genotype scores \< 0.1, and within a sliding window of 100 kb. The first four principal components (PCs) account for substantially more than the rest (cumulatively 8.8% of total variance) ([@B6]). In SHFS, the first three PCs cluster by study center and some clustering with less clear separation is apparent for the fourth PC reported in the electronic **[Supplementary Material](#SM1){ref-type="supplementary-material"}**. Family-based imputation of genotyped SNPs was done with a PEDSYS-compatible version of Merlin using human genome build 18 (NCBI36/hg18); genotype information from relatives was used to impute missing values ([@B9]; [@B35]). After imputation and quality control, 120,975 SNPs were available for analyses.

Statistical Analysis
--------------------

All analyses were performed using mixed effects models, to account for family relatedness, for quantitative traits (i.e., HOMA-IR and HOMA-B) and qualitative outcomes (incident diabetes). Analyses was implemented using Sequential Oligogenic Linkage Analysis Routines (SOLAR) assuming additive effect ([@B5]). HOMA-B values cannot be evaluated without taking HOMA-IR into account ([@B33]). Based on previous literature, we regressed HOMA-B on HOMA-IR and added the mean HOMA-B to the model residual for interpretability ([@B45]; [@B4]). These scores were called cHOMA-B and were used as traits in genetic analyses (**Supplementary Figure [1](#SM1){ref-type="supplementary-material"}**). Since HOMA-IR values were right-skewed, they were natural log transformed. For HOMA scores, models were adjusted for age at baseline, sex, and first four PCs to adjust for global population stratification. For diabetes, models were adjusted for age at follow-up (mean 42.4 years), sex, and first four PCs. Healthy controls were defined as participants who did had normal or impaired fasting glucose and who were not taking medications. Due to possible differences in allele frequencies among recruiting centers, all models were stratified by recruiting centers. The results from center-stratified association analyses were meta-analyzed using inverse-variance-weighting models implemented using METAL software ([@B44]).

The array wide significance threshold for multiple testing using Bonferroni correction was 4.13 × 10^−7^ and using the Moskvina and Schmidt method accounting for linkage disequilibrium (LD) was 7.77 × 10^−7^. We performed conditional analysis on the SNPs with lowest *p*-values to identify independent associations at each locus. Models were assessed for genomic inflation (**Supplementary Figure [2](#SM1){ref-type="supplementary-material"}**). As sensitivity analyses, we excluded participants with diabetes during follow-up for the HOMA score models. For incident diabetes, we also modified the case definition to include HbA1c thresholds and control definition to exclude participants with impaired fasting glucose. Replication of significant SNPs was assessed for nominal significance (*P* \< 0.05) in an independent sample from a community in Southwestern Arizona (*n* = 3,244) without diabetes for cHOMA-B. Models were adjusted for age, sex, and first five PCs to account for population stratification in the sample.

Results
=======

**Table [1](#T1){ref-type="table"}** shows the baseline characteristics of the study population. Over a mean follow-up of 6.6 years (12,667.6 person-years), 256 participants or 13.5% of the study population developed incident diabetes. On average, participants who developed diabetes had nearly 1 year longer follow-up than participants who did not develop diabetes. Participants developing incident diabetes were older, more often obese, and had a higher fasting glucose, HOMA-B and HOMA-IR at baseline (*P* \< 0.05). When corrected for HOMA-IR, cHOMA-B was lower among those who developed diabetes (median 158.1) compared to those who did not develop diabetes during follow-up (median 188.6) (*P* \< 0.01).

###### 

Baseline characteristics by development of diabetes during follow-up.

                                      Total                  Incident diabetes      Controls^b^            *P*-value
  ----------------------------------- ---------------------- ---------------------- ---------------------- -----------
  Sample size                         1,892                  256                    1,636                  
  Median follow-up, yrs (IQR)         6.1 (5.0--8.0)         6.9 (5.5--9.6)         6.0 (5.0--7.6)         \<0.01
  Mean age, years (SD)                36.4 (15.5)            39.2 (14.1)            36.0 (15.7)            \<0.01
  No. Female (%)                      1,140 (60.3)           146 (57.0)             994 (60.8)             0.26
  Center (%)                                                                                               \<0.01
  Arizona                             195 (10.3)             48 (18.8)              147 (9.0)              
  Oklahoma                            796 (42.1)             92 (35.9)              704 (43.0)             
  North/South Dakota                  901 (47.6)             116 (45.3)             785 (48.0)             
  Mean BMI, kg/m2 (SD)                30.4 (7.3)             35.7 (8.5)             29.6 (6.7)             \<0.01
  Mean fasting glucose, mmol/L (SD)   5.2 (0.6)              5.6 (0.6)              5.1 (0.5)              \<0.01
  Mean fasting insulin, pmol/L (SD)   115.3 (114.6)          182.7 (150.0)          104.9 (104.2)          \<0.01
  Median HOMA-IR (IQR)                2.7 (1.7--4.6)         5.0 (3.3--8.3)         2.5 (1.6--4.1)         \<0.01
  Median HOMA-B (IQR)                 155.2 (104.2--246.0)   201.0 (134.1--335.8)   148.7 (99.5--231.3)    \<0.01
  Median cHOMA-B^a^ (IQR)             186.1 (153.3--235.9)   158.1 (109.1--219.1)   188.6 (157.4--237.3)   \<0.01

a

Corrected HOMA-B; Sum of residuals adjusted for HOMA-IR and mean HOMA-B.

b

Controls are individuals that did not develop diabetes at follow-up.

The genomic inflation factor (λ) for cHOMA-B, HOMA-IR, and diabetes were 1.11, 1.02, and 1.24, respectively (**Supplementary Figure [2](#SM1){ref-type="supplementary-material"}**). We identified several genes in the Cardio MetaboChip significantly associated with cHOMA-B (*P* \< 4.13 × 10^−7^) (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**). A total of 28 variants in 25 distinct loci were statistically significantly associated with cHOMA-B (**Figure [1](#F1){ref-type="fig"}**). The associations observed near *PRSS7*, *FCRL5*, *PEL1*, *LRP12*, *IGLL1*, *ARHGEF10*, *PARVA*, and *FLJ16686* are novel for a biomarker of B cell dysfunction. *GCK* demonstrated the most consistent association with B-cell function phenotypes. In particular, rs4607517 (G \> A) was associated with a decrease in cHOMA-B of 19.54 units in SHFS (*P* = 2.67 × 10^−7^) and 11.26 in the replication sample (*P* = 0.01). The most significant SNP associated with cHOMA-B was rs2961831 (A \> C), an intergenic variant, located at 5q11/*PARP8* (**Table [2](#T2){ref-type="table"}**). Each copy of allele C was associated with increases of 23.11 units of cHOMA-B (*P* = 6.39 × 10^−9^). Of the variants, 3 regions at 5q11/*PARP8*, 12q24/*CUX2*, and 15q12/*ATP10A* had multiple variant associations that passed the significance threshold (**Figure [2](#F2){ref-type="fig"}**). Conditional analysis on index SNPs suggested the presence of a single association at each locus. Results for all significant SNP associations for log transformed HOMA-B and cHOMA-B are presented as **[Supplementary Material](#SM1){ref-type="supplementary-material"}** (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**).

![Manhattan plot of corrected HOMA-B. SNP associations mapped using NCBI36/hg18 build position. The solid line is the MetaboChip-wide Bonferroni significance threshold at −log(4.13 × 10^−7^) or 6.38. The dashed line is the MetaboChip-wide Moskvina-Schmidt LD significance threshold at −log(7.77 × 10^−7^) or 6.11.](fgene-09-00466-g001){#F1}

###### 

Main associations for cHOMA-B and log HOMA-IR.

  rsID         Chr   Position    Alleles   Gene                   Location     Strong heart family study   Replication sample                                         
  ------------ ----- ----------- --------- ---------------------- ------------ --------------------------- -------------------- --------------------- ------ -------- ------
  rs284201     1     92012826    G/A       *TGFBR3*               intron       0.27                        16.72                *2.04 × 10*^−^*^7^*   0.19   −1.75    0.72
  rs1972239    1     155775425   A/G       *FCRL5*                intron       0.18                        22.00                *3.17 × 10*^−^*^7^*   0.15   −6.06    0.25
  rs1252068    1     175868691   A/G       *LOC400796, SEC16B*    intergenic   0.35                        −18.61               *8.80 × 10*^−^*^8^*   0.45   −2.09    0.58
  rs7588499    2     54581780    A/G       *SPTBN1*               intron       0.49                        13.76                *2.06 × 10*^−^*^7^*   0.41   −1.13    0.77
  rs6748843    2     64383898    A/G       *PELI1, LOC130773*     intergenic   0.47                        18.01                *1.97 × 10*^−^*^7^*   0.35   −6.74    0.10
  rs3732678    3     12836608    A/C       *CAND2*                coding       0.25                        20.22                *1.03 × 10*^−^*^7^*   0.40   −0.10    0.98
  rs12642615   4     36914666    G/A       *FLJ16686, KIAA1239*   intergenic   0.38                        16.88                *2.02 × 10*^−^*^8^*   0.32   −0.16    0.97
  rs4139       4     163610383   A/G       *FSTL5, LOC729971*     intergenic   0.35                        16.99                *3.23 × 10*^−^*^7^*   0.35   −3.79    0.35
  rs2961831    5     50490690    A/C       *PARP8, LOC642366*     intergenic   0.40                        23.11                *6.39 × 10*^−^*^9^*   0.35   0.26     0.95
  rs2962246    5     50485571    A/G       *PARP8, LOC642366*     intergenic   0.40                        23.11                *6.39 × 10*^−^*^9^*   0.35   0.21     0.96
  rs4448128    6     116137499   C/G       *LOC441167, FRK*       intergenic   0.25                        −16.62               *4.08 × 10*^−^*^7^*   0.16   −6.92    0.18
  rs654993     6     160488886   G/A       *SLC22A1*              intron       0.23                        18.31                *7.74 × 10*^−^*^8^*   0.14   1.74     0.75
  rs38179      7     15865240    A/G       *MEOX2, LOC729920*     intergenic   0.45                        21.54                *6.26 × 10*^−^*^8^*   0.48   3.05     0.42
  rs4607517    7     44202193    G/A       *GCK, YKT6*            intergenic   0.26                        −19.54               *2.67 × 10*^−^*^7^*   0.31   −11.26   0.01
  rs7386942    8     1890157     G/A       *ARHGEF10*             intron       0.48                        −14.43               *3.94 × 10*^−^*^7^*   0.50   −7.24    0.05
  rs16872183   8     106094163   A/G       *LRP12, ZFPM2*         intergenic   0.26                        −22.62               *1.24 × 10*^−^*^7^*   0.37   −5.14    0.19
  rs10738708   9     25231316    A/C       *TUSC1, LOC10012966*   intergenic   0.43                        17.26                *3.89 × 10*^−^*^7^*   0.40   −1.91    0.61
  rs4149270    9     106686898   G/A       *ABCA1*                intron       0.23                        −22.99               *2.46 × 10*^−^*^7^*   0.18   −0.50    0.51
  rs997067     10    55709300    A/C       *PCDH15*               intron       0.37                        20.51                *2.47 × 10*^−^*^7^*   0.29   4.17     0.32
  rs4237723    11    12594808    A/G       *PARVA, TEAD1*         intergenic   0.45                        18.33                *4.82 × 10*^−^*^8^*   0.40   −3.36    0.38
  rs10777559   12    76822590    C/A       *NAV3*                 intron       0.25                        −26.21               *2.58 × 10*^−^*^8^*   0.17   −1.50    0.77
  rs10744770   12    110146961   G/A       *CUX2*                 intron       0.21                        −23.4                *1.36 × 10*^−^*^7^*   0.16   −3.87    0.45
  rs4766451    12    110155065   C/A       *CUX2*                 intron       0.22                        −23.46               *1.60 × 10*^−^*^7^*   0.17   −3.82    0.45
  rs9528062    13    59628504    G/A       *DIAPH3*               intron       0.28                        −18.51               *3.40 × 10*^−^*^7^*   0.24   −2.23    0.61
  rs883496     15    23481396    G/A       *ATP10A*               intron       0.47                        −23.44               *6.49 × 10*^−^*^9^*   0.48   1.01     0.79
  rs10152552   15    23482358    A/G       *ATP10A*               intron       0.47                        23.44                *6.49 × 10*^−^*^9^*   0.48   1.02     0.79
  rs2826602    21    21198206    G/A       *PRSS7, NCAM2*         intergenic   0.34                        −18.17               *2.49 × 10*^−^*^7^*   0.39   5.94     0.13
  rs131409     22    22221107    A/G       *LOC388882, IGLL1*     intergenic   0.27                        19.82                *2.72 × 10*^−^*^7^*   0.32   −3.28    0.42

Gene base position based on NCBI36/hg18 build. P-values of significant SNPs are italicized (

P

\< 4.13 × 10

−7

). Chr, chromosome; cHOMA-B, corrected homeostatic model assessment -- B cell function; MAF, minor allele frequency. follow-up.

![Regional association plot of PARP8, CUX2, and ATP10A for corrected HOMA-B. Multiple SNP associations for cHOMA-B are 5q11/PARP8 (top panel), 12q24/CUX2 (middle panel), and 15q12/ATP10A (bottom panel), using NCBI36/hg18 build and European American recombination rates.](fgene-09-00466-g002){#F2}

We assessed the top 28 SNPs for cHOMA-B in an independent sample from Southwestern Arizona (**Table [2](#T2){ref-type="table"}**). Variants had similar MAF in the replication sample compared to the SHFS, but we were not able to replicate many of these associations in the replication sample except rs4607517. One variant showed nominal significance; an intergenic SNP rs4607517 (G \> A; MAF in replication sample 0.31) showed an effect estimate of --11.26 (*P* = 0.01) compared to an effect estimate of --19.54 (*P* = 2.67 × 10^−7^) in the SHFS (MAF 0.26).

The top association for log transformed HOMA-IR was with rs7609071 (G \> C) near *CTNAA2* (*P* = 1.34 × 10^−5^) (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**). Each copy of the C allele was associated with an increase of 0.84 and 0.79 units of HOMA-IR in Oklahoma, and the Dakotas respectively, (effect estimate --0.18, --0.24) (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**). Other SNPs at 2p11-12 were nominally associated with cHOMA-B. In addition to being associated with cHOMA-B, rs7609071 was associated with the index HOMA-IR (*P* = 2.51 × 10^−3^) but not with incident diabetes (*P* = 0.87). There was no significant evidence for association of SNPs with incident diabetes (**Supplementary Table [1](#SM1){ref-type="supplementary-material"}**).

In the MetaboChip data, there were seven candidate diabetes loci (**Supplementary Table [2](#SM1){ref-type="supplementary-material"}**) with 1,446 SNPs that passed quality control. Among the observed associations, an intronic SNP rs163170 (*KCNQ1*) was significantly associated with HOMA-IR and with cHOMA-B (**Table [3](#T3){ref-type="table"}**). This variant is located near the previously reported SNP at this locus (rs8181588) although their correlation is low in our American Indian population (LD r^2^ = 0.29) ([@B25]; [@B15]). None of the MetaboChip SNPs in the candidate genes were associated with incident diabetes.

###### 

Main candidate gene associations for cHOMA-B and log HOMA-IR.

  rsID         Chr   Position    Alleles   MAF    Gene        Location     cHOMA-B   HOMA-IR         Diabetes                           
  ------------ ----- ----------- --------- ------ ----------- ------------ --------- --------------- ---------- --------------- ------- ------
  rs4135273    3     12414329    G/A       0.01   *PPARG*     intron       −0.01     0.01            −0.21      0.05            −0.04   0.62
  rs16860216   3     186971576   G/A       0.13   *IGF2BP2*   intergenic   0.13      0.02            −0.07      0.03            −0.03   0.57
  rs3731201    9     21978896    A/G       0.04   *CDKN2A*    intron       −0.01     0.09            −0.02      0.39            −0.01   0.76
  rs3218018    9     21988139    A/C       0.03   *CDKN2B*    intergenic   −0.06     0.18            −0.08      0.24            −0.05   0.72
  rs4639863    10    114844373   G/A       0.37   *TCF7L2*    intergenic   0.23      0.01            0.08       0.04            −0.01   0.75
  rs163170     11    2778003     G/A       0.50   *KCNQ1*     intron       0.04      6.27 × 10^−6^   −0.11      2.16 × 10^−4^   −0.01   0.92
  rs35379941   12    119909772   T/A       0.11   *HNF1A*     intron       −0.01     0.35            0.06       0.17            0.02    0.41

Gene base position based on NCBI36/hg18 build. Chr, chromosome; cHOMA-B, corrected homeostatic model assessment -- B cell function; MAF, minor allele frequency. P \< 0.05 for significant replication.

Discussion
==========

Our study validates diabetes-related loci in American Indians, a population with a large burden of diabetes. Among the SHFS participants, the diabetes prevalence was 15.6%, which is high compared to the 9.3% prevalence reported in the general U.S. population ([@B1]; [@B21]). The diabetes prevalence is especially disproportionate among younger age groups, where the crude prevalence in NHANES among 18--44 ages was 5.0% ([@B26]) compared to 12.4% in the SHFS. Our study demonstrated that known cardiometabolic loci are involved in B cell dysfunction and insulin resistance in American Indians. In particular, we identified *GCK* variant rs4607517, which was previously identified including MAGIC consortium and MESA cohort ([@B8]; [@B36]). We also identified some novel associations using the Cardio MetaboChip array, such as the association of cHOMA-B with *PARP8*. In the diabetes candidate gene analysis, we identified an association of an intronic SNP rs163170 in *KCNQ1* with both cHOMA-B and HOMA-IR.

The variants associated with cHOMA-B are located near or in genes that show involvement in biological mechanisms such as metabolism (*GCK*, *PRSS7*), movement across extracellular and intracellular membranes (*FCRL5*, *SEC16B*, *TGFBR3*, *PEL1*, *FSTL5*, *SLC22A1*, *LRP12*, *ABCA1*, *ATP10A*, *KCNJ2*, *NCAM2*, *IGLL1*), activation and deactivation of hydrolase enzymes (*ARHGEF10*, *NAV3*), transcriptional and DNA-binding regulation (*CAND2*, *ZFPM2*, *TUSC1*, *TEAD1*, *CUX2*), cell movement and adhesion (*SPTBN1*, *PCDH15*, *PARVA*, *DIAPH3*), and cell cycle and apoptosis (*FLJ16686*, *FRK*, *MEOX2*) ([@B35]). The most significant variants for cHOMA-B were located at *PARP8* \[Poly(adenosine disphosphate/ADP-ribosyl)ation -- member VIII\], which catalyze the transfer of ADP-ribose from glutamic acid to aspartic acid, possibly involving zinc fingers ([@B3]). Both *CUX2* (Cut like homeobox 2), a DNA binding motif, and *ATP10A* (ATPase phospholipid transporting 10A), a maternally expressed aminophospholipid translocase across the lipid bilayer, were previously reported in associations with diabetes related traits including metabolic syndrome ([@B39]) and insulin resistance ([@B17]). In this study, we identified associations with variants at loci not encompassed in linkage peaks on chromosomes 3 and 4 as previously reported in the SHFS ([@B29]). Our replication yielded one nominal association for rs4607517 near *GCK/YKT6* with consistent directions for the beta estimates. This was the only association that has been previously identified to be associated with HOMA-B ([@B8]). Overall, we did not find consistency between the findings in the two samples possibly due to heterogeneity between the cohorts and centers in SHFS. There may be heterogeneity in LD structure between the populations. A preliminary measure is the notable difference in MAF particularly in the variants of top candidate genes (*GCK* and *KCNQ1*). There may also be heterogeneity in measurement of variables including phenotypes that could partially account for the differences in effect sizes and statistical significance.

In analyses of diabetes candidate genes, we identified an association with several variants near *KCNQ1*, which encodes a voltage-gated potassium channel and has been associated with diabetes in individuals of European and East Asian ancestries but also in Southwest American Indians ([@B38]; [@B25]). *KCNQ1* variants showed evidence of functional effects in knockout mice ([@B15]). *In vitro* and murine studies have shown that the overactivity of the potassium channels from overexpression of *KCNQ1* can create a current across the plasma membrane and impair insulin secretion, thereby resulting in hyperglycemia ([@B25]; [@B46]). In a study among American Indians from central Arizona, *KCNQ1* variants were associated with incident diabetes ([@B12]; [@B15]). In our study, *KCNQ1* variants are related to both a decrease in HOMA-IR (effect -0.11) and with an increase in cHOMA-B (effect 0.04). ENCODE data using HaploReg (v4.0) of the diabetes candidate genes shows possible functional regulation including binding to DNA hypersensitivity site, histone promoter and enhancer sites to investigate in future studies.

Our study is one of the few that have investigated the association of genetic determinants of diabetes traits among American Indians. While the number of participants who developed diabetes was relatively small for a genetic analysis, we still identified several significant associations with cHOMA-B. The small sample size with incident diabetes could partly account for why our study was not able to replicate associations seen in other ethnic groups. The SHFS is a unique cohort especially for genetic studies because of the inclusion of related participants from complex pedigrees with high burden of diabetes. This allows for possible fine-mapping of association signals by exploiting differences in LD patterns between American Indians and European Americans among whom most association studies have been conducted. Moreover, it allows for the examination of generalizability of the detected associations in non-European American ethnic groups. We tested variants from the MetaboChip as it provides good coverage and also prioritizes cardiometabolic SNPs and thus minimizes multiple testing. Although it provides overall good coverage in different populations, the MetaboChip or any GWAS chip for that matter may miss SNPs in American Indian populations and measured SNPs may have lower allele frequencies in American Indian populations. Even so, our study was able to replicate some associations ([@B20]; [@B37]; [@B48]). While the top SNPs showed limited evidence of consistency in our replication sample, we believe this warrants further investigation of the heterogeneity of genetic susceptibility among American Indians. We observed inflation in the genomic control factor (λ) statistic. However, previous investigations in other cohorts have also reported this inflation when using the MetaboChip panel, most likely because of fine-mapping of several loci ([@B16]). In addition, none of the significant findings reported for cHOMA-B were in the loci showing deviation from the diagonal.

Also, HOMA-B and HOMA-IR are surrogate measures of B cell dysfunction and insulin resistance, respectively, and therefore may not truly reflect mechanisms of developing diabetes ([@B42]). There is limited assessment of the validity of HOMA scores, especially among various ethnic groups. [@B33] conducted a randomized control trial that highlighted the inability of HOMA-B scores to replicate the findings of laboratory measures of B cell function. Yet compared to other measures, HOMA models are favorably used in diabetes epidemiologic due to ease of measure and accuracy ([@B40]). Another caveat for HOMA-B is that it cannot be interpreted without accounting for HOMA-IR. We used methodology developed in nutritional epidemiology to account for correlated measures or as in the case with HOMA-B and HOMA-IR, measures built from similar underlying variables ([@B45]). Thus, we corrected for the influence of HOMA-IR on HOMA-B by using the HOMA-B residuals and adding a constant of mean HOMA-B. The cHOMA-B phenotype is also less well studied and therefore makes it difficult to compare with previously reported associations. Finally, we cannot discount the possibility that our incident diabetes participants include type 1 diabetes as is usual in large epidemiologic cohorts such as the SHFS. However, given that participants who developed diabetes during follow-up were middle-aged (mean 39.2 years), we believe the number of participants who may have had type 1 diabetes is low.

The novel and replicated associations for cHOMA-B provide new information of genetic association for diabetes traits in American Indians. We also validated associations of *GCK* and *KCNQ1* variants with diabetes in our study population. Although our study has a small number of incident cases and did not validate diabetes-associated loci, we identified several variants in novel loci that are hypothesis-generating for understanding genetic susceptibility in American Indians. Further studies with larger sample size and dense markers are needed to validate our results and identify additional loci unique to American Indians. Further investigation is therefore warranted to better understand the genetic susceptibility to diabetes among American Indians.
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cHOMA-B

:   HOMA-beta cell function residuals corrected for HOMA-IR

chr

:   chromosome

FPG

:   fasting plasma glucose

HOMA-B

:   HOMA-beta cell function

HWE

:   Hardy-Weinberg equilibrium

IBD

:   identity by descent

MetaboChip

:   Illumina Cardio-Metabo DNA Analysis BeadChip

MAF

:   minor allele frequency

PC

:   principal component

PCA

:   principal components analysis

SHFS

:   Strong Heart Family Study

SHS

:   Strong Heart Study

SNP

:   single nucleotide polymorphism
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